Head and neck cancer

August 17, 2021
Doctor examining patient's neck

Trial Spotlight: Dan Zandberg on the EA3191 Study for Head and Neck Squamous Cell Carcinoma

This phase II trial is comparing adjuvant treatment with either reirradiation plus pembrolizumab, pembrolizumab monotherapy, or reirradiation with platinum chemotherapy
February 25, 2021
Older patient throat exam

Now Enrolling: EA3191 for Head and Neck Squamous Cell Carcinoma

This three-arm phase II study, led by Dr. Dan Zandberg, is evaluating pembrolizumab immunotherapy after surgery in patients with recurrent or second primary head and neck cancer with high-risk features
July 29, 2020

Trial Results: E3311 Leads to Phase III Trial in Head and Neck Cancer

Learn more about a less intense treatment that preserves throat function and spares unnecessary toxicities
February 28, 2020
Dr. O'Dwyer and Dr. Schnall

From the Co-Chairs, February 2020

January meeting with NCI leaders and the Cooperative Group Chairs; Congress increases NCI and overall NIH budget for FY 2020; EA opens two new trials, one for pancreatic cyst monitoring (EA2185) and the other to evaluate nivolumab in head and neck cancer (EA3161); plans are underway for the next Comis Symposium
February 28, 2020

Trial Spotlight: Nabil Saba on Study EA3161 for HPV Positive Head and Neck Cancer

This trial is evaluating maintenance nivolumab versus observation following intensity-modulated radiation therapy and cisplatin